MYC is an oncogenic downstream target of KRAS and IL6-JAK-STAT signaling [43, 44] and therefore we correlated the expression of MYC and RASSF10 in primary renal papillary cell carcinoma and clear cell carcinoma (Fig. 6c, g). The gene discussed is IL6; the disease is clear cell adenocarcinoma.